Increased cell avidity through CD38 co-receptor drives enhanced BCMA CAR T-cell sensitivity and persistence in multiple myeloma

Title
Increased cell avidity through CD38 co-receptor drives enhanced BCMA CAR T-cell sensitivity and persistence in multiple myeloma
Reading time
15 minutes min
Collaborators
Topics

DNA-binding proteins

Download now

In this research highlight, we present cell avidity results obtained with the z-Movi® Cell Avidity Analyzer in collaboration with the team of Dr. Maria Themeli (VUMC Cancer Center Amsterdam) working on BCMA + CD38 dual-targeting CAR T therapy against multiple myeloma.

Here you will learn:
1. Cell avidity measurements with the z-Movi lead to rapid screening and identification of new, effective dual-targeting CAR T-cell therapy candidates for multiple myeloma.
2. Cell avidity measurements can be used as a tool for the pre-screening of lead CAR products at an early phase by predicting in vitro and in vivo functionality of different CAR T-cell populations.
3. Quick characterization of different CAR T-cell populations using an easy workflow.
Title
Increased cell avidity through CD38 co-receptor drives enhanced BCMA CAR T-cell sensitivity and persistence in multiple myeloma
Reading time
15 minutes min
Collaborators
Topics

DNA-binding proteins

Download now

Fill in the form